SOAT1 and myeloproliferative neoplasm: Ruxolitinib treatment was proven to have a good efficacy to reduced inflammatory signaling in patients suffering from GvHD [130] and it did also reduce the concentration of pro-inflammatory cytokines in the serum of MPN patients through blockade of JAK/STAT signaling, thereby improving the clinical response of these patients [139].